DOCSLIB.ORG

Medical Cannabis in Maryland

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medical Cannabis in Maryland 1/30/2016 MEDICAL CANNABIS IN MARYLAND PAUL W. DAVIES, M.D. NATALIE M. LAPRADE MEDICAL CANNABIS COMMISSION, CHAIRPERSON KURE PAIN MANAGEMENT, CHAIRPERSON DISCLAIMER OBJECTIVES • My comments and slides are only informational, and not authoritative. • History and background of medicinal cannabis • Basic pharmacology and physiology • You should not rely upon these slides or my comments as an authoritative • Review of clinical evidence statement of the law or the regulations. • Medical Cannabis in Maryland • The Commission and Regulations 1 1/30/2016 HISTORY OF USE OF MEDICAL CANNABIS WHAT IS MEDICAL CANNABIS? • Traditional Chinese medicine -- one of the 50 "fundamental" herbs • Medical marijuana, refers to the use of cannabis and its • Ancient Egypt, Ebers Papyrus (ca. 1550 BCE) -- used in suppositories cannabinoids to treat disease or improve symptoms for hemorrhoid pain Medical cannabis can be administered: • • Ancient India -- insomnia, headaches, gastrointestinal disorders, and • Vaporizing or smoking dried buds pain (including childbirth) • Consuming extracts • Ancient Greece -- dress wounds and sores, nose bleeds, and expel • Taking capsules tapeworms • Using oral sprays • Medieval Islamic world -- diuretic, antiemetic, antiepileptic, anti- inflammatory, analgesic and antipyretic properties MODERN HISTORY OF CANNABIS • William Brooke O'Shaughnessy (1809-1889), an Irish physician introduced cannabis to Western medicine -- muscle spasms, stomach cramps and general pain • Albert Lockhart and Manley West studied the health effects of cannabis use in Jamaican communities – in 1987 introduced the pharmaceutical Canasol • In the 1970s, a synthetic version of THC was produced and approved for use in the United States as the drug Marinol 2 1/30/2016 MEDICAL CANNABIS IN THE US MEDICAL CANNABIS IN THE WORLD • Medical cannabis legalized throughout the world: • Austria, Belgium, Canada, Czech Republic, Finland, Israel, Netherlands, Spain, the UK • 23 states and DC in the US, although it is illegal under US federal law • In the United States: • While federal law outlaws all cannabis use, legalized states no longer prosecute individuals for the possession or sale of marijuana, as long as the individuals are in compliance with the state's marijuana sale regulations PHARMACOLOGY • Genus Cannabis • Psychoactive Species • Cannabis indica • Cannabis sativa, • Less Psychoactive Species • Cannabis ruderalis • 460+ compounds (80+ cannabinoids) 3 1/30/2016 PHARMACOLOGY ENDOCANNABINOID SYSTEM • Psychoactive cannabinoid • Tetrahydrocannabinol THC (or delta-9-tetrahydrocannabinol) • Other less psychoactive cannabinoids • Cannabinoid receptors • Cannabidiol (CBD) • Predominantly located in the brain • Cannabinol (CBN) • Cannabicyclol (CBL) • Cell membrane receptors (G protein-coupled receptor) • Cannabichromene (CBC) • Cannabigerol (CBG) • Synergy produces effect • Different from our classic thinking of pharmaceuticals ENDOCANNABINOID SYSTEM (CON’T) ENDOCANNABINOID SYSTEM (CON’T) • Activators • Receptor Subtypes • Endocannabinoids (Mammillary body) • CB1 receptor • Brain (predominantly) • Plant cannabinoids • Lungs, liver and kidneys • Synthetic cannabinoids (Marinol) • CB2 receptor • Immune system • Hematopoietic cells • Novel cannabinoid receptors (non-CB1 and non-CB2) • Endothelial cells 4 1/30/2016 ENDOCANNABINOID SYSTEM (CON’T) ENDOCANNABINOID SYSTEM (CON’T) • Gastrointestinal • Physiology • Gastrointestinal activity reduced • Central Nervous System • Cardiovascular • Psychoactive • Cardiomyocytes • Coronary artery endothelial and inflammatory cells in humans and • Pain perception rodents • Appetite • Bone • Mood • Osteoblasts, osteocytes, osteoclasts • Memory • Osteoporosis CANNABINOIDS FOR MEDICAL USE: CANNABINOIDS FOR MEDICAL USE: A SYSTEMATIC REVIEW AND META-ANALYSIS A SYSTEMATIC REVIEW AND META-ANALYSIS PENNY F. WHITING, PHD ET AL. PENNY F. WHITING, PHD ET AL. • Moderate/Low quality evidence • Meta-analysis of randomized controlled studies • Fibromyalgia; • HIV-related sensory neuropathy • High quality evidence • HIV-related weight loss • Chronic pain • Multiple sclerosis • Involuntary movements • Nausea and vomiting caused by chemotherapy • Muscle spasms • Rheumatoid arthritis • Sleep disorders; • Tourette syndrome 5 1/30/2016 CANNABINOIDS FOR MEDICAL USE: A SYSTEMATIC REVIEW AND META-ANALYSIS RESEARCHERS CONCLUDED PENNY F. WHITING, PHD ET AL. • No Evidence Benefits... judged against the risks of potential side effects, such as: • Anxiety disorder • Dizziness • Depression • Dry mouth • Eye pressure • Euphoria • Psychosis • Fatigue • Nausea MEDICAL MARIJUANA FOR TREATMENT OF CHRONIC PAIN AND OTHER MEDICAL AND PSYCHIATRIC PROBLEMS: A BACKGROUND OF MMCC CLINICAL REVIEW KEVIN P. HILL MD, MSH • Critical Leadership • Review 28 randomized Clinical Trials approx 6,500 patients. • Delegates Dan Morhaim, M.D., and Cheryl Glenn • Senator Jamie Raskin • High Quality Evidence • Chronic Pain • 2013 Natalie M. LaPrade Medical Cannabis Commission (DHMH) • Neuropathic Pain • Spasticity Associated with MS 6 1/30/2016 BACKGROUND OF MMCC (CON’T) THE COMMISSION • 2013 Initial law created an academic medical center model • An independent Commission • 2014 Program expanded to include non-academic physicians • Develops policies, procedures, guidelines and regulations to • 2013-2015 Development of regulations implement medical cannabis program • 2015 (September) Regulations effective • Chair appointed by the Governor • Latest version available on Commission website: mmcc.maryland.gov THE COMMISSION OVERVIEW OF LICENSEES 16 members: • Commission is responsible for Secretary of DHMH 1 law enforcement 2 patient representatives 1attorney • Development of regulations 1 Nat’l Council on Alcohol and Drug Dependence 1 Maryland Department of Agriculture • Issue licenses 3 physicians 1 University of Maryland Extension 1 nurse 1 Office of the Comptroller • Continuous monitoring and oversight 1 pharmacist 1 Maryland States Attorneys Association 1 research scientist 7 1/30/2016 OVERVIEW OF LICENSEES (CON’T) OVERVIEW OF LICENSEES (CON’T) • 15 licensed growers initially • Independent testing laboratories to inspect all products to • Also eligible for dispensary license confirm specifications: • Licensed processors • Cannabinoid content • leaf and flowers ointments, salves, lotions, and • THC concentration vaporizable extracts • Contaminants • 2 licensed dispensaries per State senatorial district OVERVIEW OF LICENSEES (CON’T) OVERVIEW OF LICENSEES (CON’T) •Growers •Growers (con’t) • Secure building, green house or secure • Facilities and operations inspected by Commission outdoor field • Independent Testing Laboratory • Detailed security requirements • Certificate of analysis for each batch • Strict controls/standard operating • Strict inventory control procedures • Report annually minority owners and employees • Product quality and consistency 8 1/30/2016 OVERVIEW OF LICENSEES (CON’T) OVERVIEW OF LICENSEES (CON’T) •Dispensaries •Dispensaries (con’t) • Separate from growing/processing facility • Label active components and their strength • Strict security and inventory controls • Obtained from dispensary by patient and caregivers • Package plain, opaque and tamper-evident • Delivered to patient and caregivers by dispensary agents OVERVIEW OF LICENSEES (CON’T) FEES – PROGRAM NOT PAID FOR BY TAXPAYERS •Dispensaries (con’t) • Applications Grower application: • Patient education encouraged • • Stage 1: $2,000; Stage 2: $4,000 Record dispensing in Commission • • Processor application: database • Stage 1: $2000; Stage 2: $4000 • Adverse events reporting • Dispensary application: • Stage 1: $1000; Stage 2: $4000 9 1/30/2016 FEES – PROGRAM NOT PAID FOR BY TAXPAYERS PLAN FOR LICENSE APPLICATION (STAGE 1) (CON’T) • September 2015 Applications and instructions released • Annual Fees: • Grower -- $125,000 • 45 day Application period • Processor -- $40,000 • Dispensary -- $40,000 • Reviewed and ranked according to published rubric by independent • Agent registration -- $200 review team • (Grower, Processor, Dispenser, laboratory) • December 2015 likely Pre-approval of licenses • Independent Testing Laboratory -- $100 registration • LICENSE APPLICATION (STAGE 2) QUALIFYING PATIENTS • Finalizes capitalization, closes on real estate, • “Bona fide physician-patient relationship” zoning and planning approval, constructs • Register with the Commission facility, installs equipment, finishes Standard Operating Procedure, hires staff, trains staff • Establish identity • Registration number issued • Inspection, license issued, operations commence • No charge to register • Identification card, if requested, costs $50 10 1/30/2016 QUALIFYING PATIENTS (CON’T) CERTIFYING PHYSICIAN REQUIREMENTS • Limited to 30-day supply with written certification • Register with Commission • 120g "usable cannabis" or 36g of Delta 9-THC in • Register online at Commission website infused products • No registration fee • Dispensary tracks quantity dispensed • Valid for two years CERTIFYING PHYSICIAN REQUIREMENTS (CON’D) CERTIFYING PHYSICIAN REQUIREMENTS (CON’D) • Physician Attestation • Bona fide physician patient relationship • Active Medical License • Issue “Written Certification” • Unrestricted • In good standing • Registered to prescribe controlled dangerous substances in Maryland 11 1/30/2016 CERTIFYING PHYSICIANS ARE ENCOURAGED TO REGISTER TO TREAT CERTAIN CONDITIONS PHYSICIAN GENERAL REGISTRATION Chronic or debilitating disease or medical condition, or treatment, that cause: • Cachexia Certifying Physicians may
Load more

Recommended publications
  • CRESCO LABS INC. November 30, 2018 LISTING STATEMENT
    CRESCO LABS INC. November 30, 2018 LISTING STATEMENT - FORM 2A IN CONNECTION WITH THE LISTING OF THE SHARES OF CRESCO LABS INC., THE ENTITY FORMERLY KNOWN AS RANDSBURG INTERNATIONAL GOLD CORP., AFTER THE REVERSE TAKEOVER BY CRESCO LABS, LLC MARIJUANA IS ILLEGAL UNDER U.S. FEDERAL LAW AND THE ENFORCEMENT OF RELEVANT LAWS IS A SIGNIFICANT RISK. Cresco Labs Inc. indirectly holds all the voting interests and an approximate 53% equity interest in Cresco Labs, LLC, the entity through which all of the operating subsidiaries of Cresco Labs, LLC are held. Shareholders are cautioned that at this time, the outstanding Subordinate Voting Shares and Proportionate Voting Shares does not represent all of the equity interest in Cresco Labs, LLC. Cresco Labs Inc. derives a substantial portion of its revenues from the cannabis industry in certain states of the United States, which industry is illegal under United States federal law. Cresco Labs Inc. is indirectly involved (through its licensed subsidiaries) in the cannabis industry in the United States where local state laws permit such activities. Currently, its subsidiaries are directly engaged in the manufacturing, possession, use, sale or distribution of cannabis in the recreational and/or medicinal cannabis marketplace in the States of Illinois, Pennsylvania, Ohio, Nevada, Arizona and California and will begin such activities in New York, Massachusetts and Maryland in the near term. The United States federal government regulates drugs through the Controlled Substances Act, 21 U.S.C. § 811 (the "CSA"), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug.
    [Show full text]
  • Fact Sheet Medical Cannabis & Housing
    Medical Marijuana & Housing Fact Sheet Medical Cannabis & Housing Medical Cannabis in Maryland: Overview ● In 2013, the Maryland General Assembly enacted the state’s first legislation creating a framework for the medicinal use of cannabis. Chapter 403 of the Acts of MD 2013 ● A “qualifying patient” may possess up to a 30-day supply of medical cannabis without being subject to arrest, prosecution, or any civil or administrative penalty. The Natalie LaPrade Medical Cannabis Commission will determine what constitutes a 30-day supply. Health-General Article 13–3313(a). ● On June 26, 2015, the Commission published proposed regulations governing the growth, sale, distribution, possession and use of medical cannabis. Maryland Register, Vol. 42, Issue 13, pages 812-45 (June 26, 2015). The comment period closed July 27, 2015, and final regulations are anticipated soon. At this time, medical cannabis is not available for sale or use in Maryland. Federal Law Concerning Marijuana Under the federal Controlled Substances Act, marijuana is categorized as a Schedule 1 drug that has a high potential for abuse and no accepted medical use in treatment in the United States; therefore, use and possession are illegal. 21 U.S.C. §812 Schedule 1(c)(17) ● Despite federal law, as of April 2015, at least 23 states, along with the District of Columbia and Guam, have passed laws exempting qualified users of medical marijuana from penalties imposed under state law, and created state medical marijuana programs. See Colorado Medical Marijuana Code, C.R.S. 12-43.3- 101 et seq.; Hawai’i Uniform Controlled Substances Act, Haw. Rev.
    [Show full text]
  • Medical Cannabis Comes in Many Forms Alternative Methods of Cannabinoid Delivery
    OUR LOGO Hamsa A universal symbol of Peace, Hope, Protection, and Healing. Treasured by Muslims, Christians, Jews and others, both the Hebrew word “hamesh” and the Arabic word hamsa have the same source, meaning “five”, hence the hand representing - Peace, Hope Protection and Healing OUR MISSION… to provide you with the best patient experience possible, in a professional, warm, and comfortable environment, offering the highest quality and largest variety of medicinal grade marijuana and marijuana concentrates, as well as books and accessories, at great prices. TAKOMA WELLNESS CENTER HOURS OF OPERATIONS Monday – Friday 1:00 pm – 7:00 pm Saturday CLOSED Sunday 11:30 am – 5:00 pm 2001 IOM Quality Chasm Report CANNABIS Cannabinoids: 3 Varieties Endocannabinoids (Di Marzo 1998): natural endogenous compounds binding cannabinoid receptors (e.g., anandamide and 2-AG Arachidonoylglycerol) whose functions are: “relax, eat, sleep, forget and protect” in human beings Phytocannabinoids (Pate 1994): terpenophenolic 21-C plant compounds found in the genus Cannabis (e.g., THC, CBD) Synthetic Cannabinoids (e.g., ajulemic acid) that also affect cannabinoid receptors. Dronabinol (e.g. Marinol) Russo, E.B. 2008. Cannabinoids in management of difficult to control pain. Therapeutics & Clinical Risk Management 4(1):245-259. Phytocannabinoids: Produced in Trichomes ➢THC and other cannabinoids are produced in the trichomes ➢Trichomes are predominant in the flowers and leaves of the female Cannabis plant Cannabis sativa plant Terpenes: Smells & Therapeutic Effects SATIVA Sativa plants are used most commonly to elevate a depressed mood. Primarily the effects of sativas are on the mind and emotion. They tend to more stimulating, uplifting, energizing, and creativity enhancing.
    [Show full text]
  • Cannabis MAPA19.Pptx
    8/2/19 Objectives 1. Explore who is eligible to obtain medical cannabis (marijuana). 2. Outline the process to receive an order for Medical Marijuana in Maryland medical cannabis. 3. Understand the various types of medical cannabis products available in Maryland. 4. List the three components of the medical cannabis market in Maryland. 5. Describe the number of dispensary locations in Maryland. Source: National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services History of Cannabis • Documented in Chinese literature back to The 2700 BC GOOD • Netherlands back to 2459 BC • Used in Ayurvedic medicine back to 1700 BC Cannabis • 1550 BC Egyptian prescription found • 500 BC a Greek description of cannabis steam baths The The BAD UNKOWN Marijuana in Maryland Medical Cannabis in Maryland • 2013 bill signed for medical marijuana program • 2014 bill passed to decriminalize possession of 10 grams or less • September 2015 Maryland Medical Cannabis Law passed For Whom? • 2016 public smoking or possession of marijuana paraphernalia decriminalized (civil infraction with How? fine vs criminal charge) • 2017 bill to approve recreational marijuana did When? By Whom? not pass Photo Source: National Institutes of Health; U.S. Department of Health and Human Services 1 8/2/19 Maryland Medical Cannabis Medical Cannabis in Maryland Commission • MMCC develops policies, procedures, • Growers (14) regulations • Processors (12) • Named in honor of Natalie M Laprade • Dispensers (77 – will be up to 102) – Mrs. Laprade was mother of Baltimore City – 2 allowed per state senate voting district Delegate Cheryl Glenn. • Independent Laboratory – Mrs. Laprade died of kidney cancer; Delegate Glenn believes medical cannabis could have benefited her mother.
    [Show full text]
  • Medical Cannabis Maryland
    DEPARTMENT OF COMMUNITY RESOURCES INTEROFFICE MEMORANDUM TO: Board of County Commissioners VIA: Terry L. Shannon, County Administrator 115 FROM: Maureen T. Hoffman, Director DATE: July 22, 2016 SUBJECT: Dr. Mishka Terplan — Medical Cannabis Presentation Background: Dr. Mishka Terplan, Master of Public Health (MPH), Fellow of the American College of Obstetricians and Gynecologists (FACOG) Diplomat, American Board of Addiction Medicine (ABAM) certified, serves as the Medical Director for Behavioral Health System Baltimore (BHS). He joined BHS in 2014 and provides senior level medical and clinical management support, participates in quality assessment and improvement initiatives, and takes part in a variety of city-wide public health programs. Discussion: You have requested that Dr. Terplan be placed on the agenda to present information on medical cannabis during a weekly BOCC meeting. Conclusion/Recommendation: Please allot time during your September 13, 2016, BOCC meeting for Dr. Terplan to present (using the attached Power Point) information on medical cannabis. Fiscal Impact: None Copy: Dr. Laurence Polsky, Health Officer Medical Cannabis Maryland Mishka Terplan MD MPH FACOG FASAM Medical Director Behavioral Health System Baltimore Cannabis is … • Probably the most • A high potential for satisfactory remedy for abuse and no accepted the treatment of medical value migraine headaches • Controlled Substance Act 1970-2016 – Dr William Osler, Textbook of Medicine 1892-1915 2 Terminology • Cannabis Plant Names • Categories of – Hemp Cannabinoids • Refers to plant and its product – Phytocannabinoids • Oldest term • 104 cannabanoids – Marijuana • 545 total compounds • Refers to both plant and drug – Endocannabinoids • New “slang” term • 4+ cannabinoids – Cannabis – Synthetic cannabinoids • Refers to both plant and drug • Multiple – pharmaceutical and • DSM-5 “most appropriate scientific recreational term” 3 Cannabis: A Unique Plant • Source of 3 important types of products 1.
    [Show full text]
  • Medical Supply in Jeopardy As More States Legalize Adult-Use Cannabis
    Cannabis Policy Medical Supply in Jeopardy as More States Legalize Adult-Use Cannabis he year 2020 brought a tsunami of events that led to Ms. Althoff confirmed a shortage in cannabis flower for a rise in demand and a fall in supply of medical can- medical use in 2020 and said that although the shortage was nabinoid products in the United States. AJEM spoke initially anticipated, it was exacerbated by a number of oth- Twith officials and physicians from 3 states that were reporting er variables that occurred. The industry prioritized medical cannabis shortages—Illinois, Maryland, and Florida—about patients and collaborated to ensure that there were regional its effect on patients. Additionally, panic-related buying due balances in medical and recreational cannabis supplies, with to the COVID-19 crisis created supply issues in the United all licensed cultivators expected to reach full capacity by the States and around the globe. Experts paint a cautionary tale end of 2020, Ms. Althoff told AJEM. According to an article for the medical supply as more states move toward legalizing in the Chicago Sun Times dated February 3, 2021, operators recreational cannabis. at dispensaries note that, for the most part, the supply issue has been resolved.1 A Perfect Storm in Illinois The bill to legalize recreational cannabis in Illinois was The undersupply of medical cannabis flower throughout the signed by Governor JB Pritzker on June 25, 2019, theoret- state of Illinois resulted from the interplay of several factors ically allowing for a 6-month ramp-up in production before including the legalization of recreational cannabis, an in- recreational sales began on January 1, 2020.
    [Show full text]
  • Management Discussion and Analysis for the Three Months Ended June 30, 2018
    Management Discussion and Analysis For the Three Months Ended June 30, 2018 The following Management’s Discussion and Analysis (“MD&A”) of financial condition and results of operations dated August 29, 2018 relates to unaudited interim condensed consolidated financial statements for the three months ended June 30, 2018 of MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation) (“MPX” or the “Corporation”). This MD&A should be read together with the Corporation’s unaudited interim condensed consolidated financial statements for the three months ended June 30, 2018 together with the related notes as well as the audited consolidated financial statements for the years ended March 31, 2018 and March 31, 2017 together with the related notes. MPX’s consolidated financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”) which requires management to make certain estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and the amount of revenue and expenses incurred during the reporting period. The results of operations for the periods reflected herein are not necessarily indicative of results that may be expected for future periods. Certain statements in this MD&A may contain “forward-looking information”, within the meaning of applicable securities laws, including “safe harbour provisions” of the Securities Act (Ontario) with respect to the Corporation and its subsidiaries. Such statements include, but are not limited to, statements about the growth of the business, production and revenue expectations and the licensing of facilities. These statements are subject to certain risks, assumptions and uncertainties that could cause actual results to differ materially from those included in the forward- looking statements.
    [Show full text]
  • Hashish in Islam 9Th to 18Th Century Gabriel G
    814 HASHISH IN ISLAM 9TH TO 18TH CENTURY GABRIEL G. NAHAS, M.D. Department of Anesthesiology Columbia University College of Physicians and Surgeons New York, New York C ANNABIS was used as an intoxicant @hang) in India and Iran as far back as 1000 B.C.1,2 It was adopted in the Moslem Middle East 1,800 years later, two centuries after the death of the prophet Mohammed. Indeed, during his life time (A.D. 570-632), the use of cannabis prepara- tions (known in the Middle East as hashish, which means "grass" in Arabic) was unknown. This might be the reason why the prophet did not explicitly forbid in the holy Koran intoxication by cannabis, although he proscribed that induced by fermented beverages (alcohol, wine, beer). There is no evidence that the Arabs became familiar with the intoxicat- ing properties of hashish before the ninth century. At that time, they had already conquered Iraq and Syria and swept eastward to the border of Persia and Central Asia and westward through Asia Minor, North Africa, and Spain. (It was in 752 that the relentless Muslim expansion was halted at Poitiers by the Frankish king Charles Martel.) In the ninth century, well after the establishment in A.D. 750 of the splendid Abasside caliphate in Bagdad, noted for its universities, Arab scholars translated the Greek texts of Dioscorides and Galen, and became familiar with the medicinal properties of cannabis. One physician of the early 10th century, Ibn Wahshiyah, warned of possible complications resulting from use of hashish. In his book, On Poisons, he claimed that the plant extract might cause death when mixed with other drugs.
    [Show full text]
  • Medical Marijuana for Cancer Patients
    Medical Marijuana (Cannabinoid-Derived Products) for Cancer Patients 38 accc-cancer.org | May–June 2020 | OI BY MELODY CHANG, RPH, MBA, BCOP annabis, also known as marijuana, or called a vast number of other slang terms like weed, herb, pot, grass, bud, ganja, and Mary Jane originated in Central Asia but is grown Each state has its own list of the Cworldwide today. Cannabis use for medicinal purposes dates qualifying conditions for which it will back at least 5,000 years, with the earliest reported use being in China around 2700 BC for the relief of pain and cramps.1 allow patients to use medical marijuana. In the United States, cannabis is still a controlled substance These qualifying conditions are different and is classified as a Schedule I agent (a drug with a high potential for abuse and currently no accepted medical use). The U.S. Food in each state; however, in many states and Drug Administration (FDA) has not approved cannabis as a number of conditions are cancer a treatment for cancer or any other medical condition. By federal law, the possession of cannabis is illegal, except within approved related—chemotherapy-induced nausea research settings. However, a growing number of states, territories, and vomiting, anxiety, hepatitis C, and the District of Columbia have enacted laws that decriminalized the recreational and/or medicinal use of marijuana in that specific HIV/AIDS, cachexia (wasting syndrome), area. Cannabis is the fastest growing industry in the world. Accord- and inflammatory bowel disease. ing to Arcview’s market research, regulated marijuana sales in North America totaled $6.9 billion in 2016.
    [Show full text]
  • Recognizing the Environmental Concerns Facing the Cannabis Industry
    HOW GREEN IS THE “GREEN RUSH”? RECOGNIZING THE ENVIRONMENTAL CONCERNS FACING THE CANNABIS INDUSTRY Christopher D. Strunk,1 Of Counsel Mackenzie S. Schoonmaker,2 Shareholder Introduction ............................................................................................... 507 I. Litigation Risks ...................................................................................... 508 a. Products liability ............................................................................... 509 b. Civil RICO Claims ............................................................................ 513 b. Nuisance Claims ............................................................................... 515 c. Targeting of the Cannabis Industry in California with Environmental Laws ................................................................................................ 516 1. Safe Drinking Water and Toxic Enforcement Act of 1986 (Prop 65) ...................................................................................................... 516 2. California Environmental Quality Act (CEQA) ........................... 517 II. Environmental Regulatory Concerns ................................................... 517 a. Water ................................................................................................. 517 b. Air ..................................................................................................... 519 1. Christopher D. Strunk is Of Counsel at Beveridge & Diamond P.C. in San Francisco, where his practice focuses
    [Show full text]
  • WHO Expert Committee on Drug Dependence Critical Review
    WHO Expert Committee on Drug Dependence Critical Review …………….. Cannabis and cannabis resin This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization © World Health Organization 2018 All rights reserved. This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]
  • Medical Cannabis in Maryland: the Science
    A New Frontier: The Evolving Legal and Policy Landscape of Medical Cannabis in Maryland: The Science Patricia C Frye, MD Certified Medical Cannabis Specialist Takoma Park Integrative Care Author of “The Medical Marijuana Guide: Cannabis and Your Health” Ancient Medicine • First cultivated crop – 12,000 years • Used as medicine – 5000 years • TCM – 2700 BC • Egyptian Papyri – 1400 BC • First Anesthetic – 150 AD • Ayurveda • Ancient Islamic Medicine • Western Medicine – 1830’s • US Pharmacopoeia – 1857 -1942 • Appetite • Sleep • Stress • Emotions • Memory • Pain • Fat, glucose metabolism • Autoimmune system Endocannabinoid System (ECS) Endocannabinoid System (ECS) • CB1 – primarily brain, CNS Receptors: • CB2 - tissues, organs, immune cells • Others: GPR55, TRPV, IL, TNF, 5-HT • Anandamide, 2-AG, PEA • Produced on demand Endocannabinoids: • Act locally • Bind to transmembrane G-protein receptors principally inhibiting neurotransmitter release • Inactivated rapidly • Fatty Acid Amide Hydrolase (FAAH) Enzymes: • Monoarachylglycerol Lipase (MAGL) Pain Neuron Anandamide 2-AG PEA CB1 AEA Release of Ca+, Glutamate, GABA Serotonin X Activation of lipid precursors forms AEA Dopamine Immunomodulation • Increases interleukin l • Decreases interleukin ll • Decreases interferon production • Suppresses natural killer cell activity • Increases release of pro-inflammatory cytokines • Therefore immunomodulating, not immunosuppressing What we know What we don’t know due to federal restrictions on clinical trials It’s All Cannabis • Marijuana = >0.3% THC
    [Show full text]